The Hidden Pitfalls of Unconscious Bias in Drug Development

Please be assured this is not a woke rant dealing with micro-aggressions or cultural stereotyping, but about something potentially much more impactful on drug development outcomes. It deals with the...
Learn More

The Perils of Misaligned Incentives: Why Drugs Fail Late in Development

Intro The journey of a drug from conception to market is notoriously fraught with challenges. In the high-stakes world of biotech and pharmaceutical development, it can be particularly damaging to...
Learn More

Using rNPV analysis in deal term negotiations

Intro We are often asked by clients how they can use a risk-adjusted net present value (rNPV) for deal term negotiations for an asset. The rNPV methodology is discussed in depth in several of our...
Learn More

Extracellular vesicle (EV) therapeutics: good things in small packages

Extracellular vesicle (EV) therapeutics: good things in small packages Once considered simply as byproducts of cellular recycling and waste management, extracellular vesicles (EVs) have become the...
Learn More

Disease Indication Strategy for Anti-Fibrotic Drugs

Introduction: Anti-fibrotic drug candidates, prior to entering clinical development, often have a mechanism of action that may be beneficial for treatment of multiple diseases. Early strategic issues...
Learn More

Obesity: Beyond Getting Slim Quick & GLP-1s

Looking Beyond GLP-1s Currently, much of the pharmaceutical industry and up to a quarter of the population of the developed world are captivated by get-slim-quick drugs known as GLP-1 agonists, and...
Learn More

The financing dose-response curve: how much is too much?

For biotechs, how much is too much? We’re all too aware of the rate of biotech company failures at the moment. This includes venture-backed companies that have raised well in excess of $100m,...
Learn More

What’s Bugging You? The Next Chapter for Microbiome Drugs

Depending on your perspective, live biotherapeutic products (LBPs) are either a promising, newly emergent class of therapeutic agents that utilize live microorganisms to prevent or treat various...
Learn More

TTOs: Lost in Translation?

It's not business as usual: While the halls of biopharma partnering conferences have refilled, it is definitely not business as usual in the industry. Valuations are down sharply from their pandemic...
Learn More

Is it ever too early to consider new drug pricing strategy?

Is it ever too early to consider new drug pricing strategy?
Learn More

Planning for Pharma Partnering

It's never too early to start For biotechs developing an asset for a pharma partnership, it’s crucial to consider the key deal-success ingredients, in the eyes of a future pharma partner, well in...
Learn More

Experts and Witnesses: Two Sides of the Same Coin

It surprises, and occasionally alarms, even experienced experts familiar with undertaking due diligence on behalf of investors or corporations to realize their knowledge, skills and attributes make...
Learn More
1 2 3 4 5 ... 6
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.